ClinicalTrials.gg
RecruitingNCT04792489Updated Jul 13, 2026

DALY II USA/ MB-CART2019.1 for DLBCL

A Phase 2 interventional study of zamtocabtagene autoleucel (MB-CART2019.1) and Cyclophosphamide in Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma and High Grade B-cell Lymphoma (HGBCL), sponsored by Miltenyi Biomedicine GmbH. Recruiting at 32 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Miltenyi Biomedicine GmbH · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
315
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States — 126 open to participants now, 217 under way, 18 of them phase 3. Lymphoma, Large B-Cell, Diffuse · United States.

Planned enrollment
54th of 963
315 · median 37
Started
2021
with 41 others
Phase 2
380 of 1,131
47 open now
Primary completion
2026-12
later than 61 of 216 live
Registered
931st of 1,131
by date

Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, this one is the 54th largest by planned enrollment of the 963 interventional ones that give a count, is one of 42 that started in 2021, is one of 380 in phase 2, reaches primary completion later than 61 of the 216 other live ones, and was the 931st registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

126 of the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, or all of them as a file.
02

Study summary

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts include subjects with diffuse large B-cell lymphoma (DLBCL) after receiving at least 2 lines of therapy, primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL) after receiving at least one line of therapy, mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least one line of therapy, and DLBCL transplant-ineligible after receiving at least one line of therapy.

Read the detailed description

A prospective, single arm, open label, multi-center, phase II study of autologous T cells engineered against both CD19 and CD20 antigens for subjects with relapsed or refractory DLBCL after receiving at least two lines of therapy. The investigational agent is the MB-CART2019.1 cells. Additional cohorts include transplant-ineligible subjects with relapsed and/or refractory DLBCL after first-line therapy (i.e. DLBCL transplant-ineligible 2nd-line), r/r B-cell primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL), mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least one line of therapy. After successful screening, subjects will undergo leukapheresis to collect product for manufacturing. In preparation for the fresh product infusion, subjects will undergo a lymphodepleting regimen with cyclophosphamide and fludarabine, or bendamustine. Cell infusion will be administered intravenously at a dose of 2.5 x 106 CAR+ cells/kg body weight. The study will start with enrollment of 3 subjects in the lead-in safety phase, and after safety is evaluated, the study will continue with enrollment of the remaining subjects. Subjects will be followed for up to 2 years, for efficacy and safety outcomes as well as health-related quality of life (HRQol). Additional long-term follow-up will be conducted for participants under a separate long-term follow-up protocol.

03

Conditions studied

  • Refractory Diffuse Large B Cell Lymphoma (DLBCL)
  • Relapsed Diffuse Large B Cell Lymphoma
  • High Grade B-cell Lymphoma (HGBCL)
  • Primary Mediastinal B-cell Lymphoma (PMBCL)
  • Transformed Lymphoma
  • Central Nervous System Lymphoma
  • Mantle Cell Lymphoma (MCL)
  • Richter Transformation
  • Transplant-ineligible 2nd Line DLBCL

Keywords

  • CD19/CD20-directed CAR-T Cells
  • Zamtocabtagene autoleucel
  • B-Cell Non-Hodgkin Lymphoma
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • NHL
  • PCNSL
  • SCNSL
  • Chimeric Antigen Receptor
  • CAR
  • CAR-T Cell
  • Autologous T Cell Therapy
  • Central Nervous System Neoplasms
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • MCL
  • RT
  • CLL
  • Immunotherapy
  • T cells
  • T cell infusion
  • transplant-ineligible 2nd line DLBCL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed B-cell non-Hodgkin's lymphoma:

    • DLBCL cohort (both cohorts)
  • DLBCL or associated subtype, defined by WHO 2016 classification
  • DLBCL not otherwise specified (NOS)
  • High-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
  • High-grade B cell lymphoma (NOS)
  • Primary mediastinal (thymic) large B cell lymphoma
  • Transformed lymphoma (e.g., transformed follicular, or marginal zone lymphoma, follicular lymphoma (FL Grade 3)

    o CNS cohort

  • B-cell primary or secondary central nervous system lymphoma (PCNSL or SCNSL)

    o Mantle Cell Lymphoma (MCL) cohort

  • Histologically confirmed MCL determined by overexpression of cyclin D1 or presence of t(11;14) (q13; q32) translocation

    o Richter's Transformation (RT) cohort

  • Histologically confirmed RT to a diffuse large B-cell lymphoma (DLBCL) subtype from underlying CLL (clonally related)
  • disease is defined for DLBCL (and associated subtypes) population as:

For DLBCL cohort (after receiving at least two ): persistent disease after failure of 2 or more lines of chemotherapy including rituximab or equivalent and anthracycline and either after failed , or ineligible, not intended for or not consenting to ASCT

  • Chemotherapy-refractory disease (applies to all cohorts) is defined as persistent disease after last line of therapy or relapsed or persistent disease after prior ASCT for lymphoma
  • Disease relapse in subjects without prior ASCT is defined as relapse of disease after the last dose of most recent therapy regimen

For disease specific cohorts added after the initial DLBCL cohort the definition of relapsed/refractory disease is as described below:

CNS cohort: Subjects with relapsed/refractory PCNSL that have failed (or unable to tolerate) at least first-line therapy.

  • First-line therapy is defined as either high dose methotrexatebased therapy, temozolomide, high dose cytarabine, pemetrexed, lenalidomide or Bruton tyrosine kinase (BTK) inhibitor-based therapy.
  • No for MRI evaluation
  • CNS cohort: Subjects with SCNSL must have relapsed or refractory disease after having received at least one prior line of systemic therapy
  • Prior lines of systemic therapy should include an anti-CD20 monoclonal antibody and anthracycline containing chemotherapy regimen and/or with or without an autologous stem cell transplant

MCL cohort: Subjects with relapsed/refractory disease after at least one prior systemic treatment, that must include:

  • Cytotoxic rituximab [or equivalent] based chemotherapy regimen (eg, rituximab bendamustine, R-CHOP, R-DHAP, R-ARA-C) AND
  • BTK inhibitor

RT cohort: Subject must have relapsed/refractory disease after at least one prior systemic treatment following Richter's Transformation

DLBCL transplant ineligible 2nd cohort: subject must have failure of first-line chemotherapy (including rituximab or equivalent and anthracycline).

  • For this cohort subjects are considered transplant ineligible if they meet one of the following criteria:
  • Age ≥70 years
  • status is 2 at screening
  • Impaired pulmonary function: diffusing capacity of the lung for carbon monoxide [DLCO] ≤ 60% adjusted for gender-specific concentration (Coates formula)
  • Impaired cardiac function: (LVEF) \< 50%; must be assessed by echocardiogram or multiple uptake gated acquisition (MUGA) scan performed within 4 weeks of determination of eligibility
  • Impaired renal function: calculated (Cockcroft and Gault) \< 60 mL/min
  • Impaired hepatic function: (AST)/alanine aminotransferase (ALT) > 2 x (ULN)

In addition, all subjects must have:

  • Age ≥18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status that is either 0 or 1 at screening. ECOG performance status of 2 at screen is allowed if the decrease in performance status is due to lymphoma

    • Subjects in DLBCL transplant-ineligible 2nd-line cohort with ECOG performance status of 2, regardless of attribution, will be allowed for inclusion
  • will be assessed by FDG-PET/CT in systemic lymphoma . and by brain/spine MRI for CNS disease
  • Subject must have a tumor sample (at least 16 unstained slides of tissue or tissue block) from the most recent relapse available prior to MB-CART2019.1 infusion. If medically not feasible to obtain a biopsy from the most recent relapse and for cases when the amount of tissue is limited, the sponsor should be consulted, to confirm adequacy of the sample for study required analyses
  • No clinical suspicion of central nervous system (CNS) lymphoma (not applicable to CNS cohort)

    • Subjects in DLBCL transplant-ineligible 2nd-line cohort with SCNSL will be allowed for inclusion
  • If the subject has history of CNS disease (not applicable to CNS cohort), then he/she must have no signs or symptoms of CNS disease, have no active disease on magnetic resonance imaging (MRI), have no large cell lymphoma present in cerebral spinal fluid (CSF), regardless of the number of white blood cells (WBCs)
  • If has history of cerebral vascular accident (CVA), the CVA event must be greater than 12 months prior to leukapheresis. Any neurological deficits must be stable
  • A creatinine clearance (as estimated by direct urine collection or Cockcroft-Gault Equation) > 45mL/min
  • Cardiac ejection fraction (EF) ≥ 45% as determined by an echocardiogram (ECHO) or Multigated Radionuclide Angiography (MUGA)
  • Subjects in DLBCL transplant-ineligible 2nd-line cohort with a lower ejection fraction of > 40% will be allowed for inclusion
  • Resting O2 saturation >90% on room air
  • Serum alanine aminotransferase (ALT) / aspartate aminotransferase (AST)\<5 times the Upper Limit of Normal (ULN) for age
  • Total \<1.5 mg/dl, except in individuals with Gilbert's syndrome
  • Subjects in DLBCL transplant-ineligible 2nd-line cohort with a total bilirubin of \< 2.0 mg/dL will be allowed for inclusion
  • (ANC) > 1000/μL
  • Absolute lymphocyte count > 100/μL
  • count > 50,000/µL
  • Estimated of more than 3 months other than primary disease

Exclusion criteria

Exclusion Criteria:

  • Primary CNS lymphoma (not applicable to CNS cohort)
  • Richter's transformed DLBCL arising from chronic lymphocytic leukemia (CLL) (not applicable to RT cohort)
  • Unable to give
  • Known history of infection with (HIV) or active (HBsAg positive). If there is a history of treated hepatitis B or , the viral load must be quantitative polymerase chain reaction (PCR) negative; antiviral prophylaxis is required if HBsAg negative and anti-HBc positive
  • Known history of infection with hepatitis C virus (anti-HCV positive) unless viral load is undetectable per quantitative PCR and/or nucleic acid testing.
  • Pharmacologically uncontrolled seizures.
  • Known history or presence of CNS disease, such as multiple sclerosis, optic neuritis, or other immunologic or inflammatory disease
  • Presence of CNS disorder that, in the judgment of the Investigator, may impair the ability to evaluate neurotoxicity. For CNS Cohort:

    • For CNSL and DLBCL transplant-ineligible cohort patients that have a CNS lesion(s): Midline shift on MRI or Abnormal high CSF opening pressure and or CSF protein ≥150 mg/dL Recent (within 3 months) whole brain radiotherapy (WBRT) are exclusionary
  • Active systemic fungal, viral, or bacterial infection
  • Pregnant or breast-feeding woman
  • Previous or concurrent with the following exceptions:

    • Adequately treated basal cell or squamous cell carcinoma (adequate wound healing required prior to study entry)
    • In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 2 years prior to the study
    • Adequately treated breast or prostate carcinoma on hormonal therapies such as Lupron or tamoxifen and in clinical remission of ≥ 2 years
    • A primary malignancy which has been completely resected / treated with curative intent and in complete remission of ≥ 2 years
  • Severely subjects e.g., due to current treatment of non-neurologic autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus).
  • Medical condition requiring prolonged use of systemic equivalent to prednisone >10 mg/day. For CNS cohort: Up to 2 mg/day dexamethasone (or equivalence) may be allowed at any time, higher doses allowed up to 7 days prior to apheresis or after apheresis until lymphodepletion.
  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other cardiac disease within 6 months of enrollment.
  • Concurrent radiotherapy (allowed up to time of lymphodepletion). For prior systemic therapy, at least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed at the time of scheduled leukapheresis.
  • Baseline dementia that would interfere with therapy or monitoring, determined using Immune Effector Cell-Associated Encephalopathy (ICE) Assessment at baseline.
  • History of severe immediate reaction to any of the agents used in this study.
  • Refusal to participate in additional lentiviral gene therapy long-term follow-up (LTFU) protocol
  • Prior CAR-T therapy for any indication or systemic gene modifying therapy for B-cell lymphoma
  • Prior stem cell transplant for any indication
  • Prior Bispecific T cell engaging (BITE) antibodies for cancer therapy
  • Prior T cell receptor-engineered T cell therapy
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
315 participants (estimated)

Study arms

  • Experimental
    Single, open label

    Biological: zamtocabtagene autoleucel (MB-CART2019.1) · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Bendamustine

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    ORR

    Time frame: through study completion, up to 2 years

Secondary outcomes

  1. Complete Response Rate

    CRR

    Time frame: 1 and 6 months

  2. Duration of Response

    DOR

    Time frame: Up to 2 years

  3. Overall Response Rate

    ORR

    Time frame: 1 and 6 months

  4. Best Overall Response

    BOR

    Time frame: 2 years

  5. Duration of Complete Response

    DOCR

    Time frame: 2 years

  6. Progression Free Survival

    PFS

    Time frame: Up to 2 years

  7. Overall Survival

    OS

    Time frame: Up to 2 years

  8. Type, frequency, and severity of adverse events

    Safety

    Time frame: Up to 2 years

  9. Incidence of anti-MD-CART2019.1 antibodies

    Bioanalytical

    Time frame: Up to 2 years

  10. Phenotype of MB-CART2019.1

    Bioanalytical

    Time frame: Up to 2 years

  11. Persistence of MB-CART2019.1

    Bioanalytical

    Time frame: Up to 2 years

  12. Quality of Life (QoL) assessments [EQ-5D-5L]

    Health Outcomes - Standardized 5 question measure of health status developed by the EuroQol Group

    Time frame: Up to 2 years

  13. Patient-Reported Outcome (PRO) assessment [FACT-Lym]

    Health Outcomes - To address health-related quality-of-life (HRQL) issues for Non-Hodgkin's lymphoma (NHL) patients

    Time frame: Up to 2 years

  14. Pharmacodynamics [Levels of cytokines in blood]

    Bioanalytical

    Time frame: Up to 2 years

  15. Correlation of tumor CD19 and CD20 antigen expression with disease progression and relapse

    Bioanalytical

    Time frame: Up to 2 years

07

Study locations

30 of 32 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Dec 2026, 67 months after the start.

Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's planned 67 months is above that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2021
First posted
Mar 11, 2021
StartActual
May 25, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04792489
Lead sponsor
Miltenyi Biomedicine GmbH
Responsible party
Sponsor
First posted
Mar 11, 2021
Start date
May 25, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 13, 2026

Study contacts

Ron Gomez
Contact
clinicaltrials@miltenyi.com
617-218-0044
Harshita Gahankari
Contact
clinicaltrials@miltenyi.com
617-218-0044
Johanna Theruvath, MD
study director · Miltenyi Biomedicine GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zamtocabtagene autoleucel

Start the discussion